Pharmaceutical

Lexicon plans another bid for Zynquista in type 1 diabetes

Despite failing to get an approval for type 1 diabetes in 2019, Lexicon plans to resubmit its NDA to the FDA by mid-2024.

May 5, 2024 - 00:00
Lexicon plans another bid for Zynquista in type 1 diabetes
Despite failing to get an approval for type 1 diabetes in 2019, Lexicon plans to resubmit its NDA to the FDA by mid-2024.
Read the original article

Tags:

Previous Article

FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy 

Next Article

ESCMID 2024: Advances in drug resistance testing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

SK Bioscience gains UK authorisation for SKYCovion Covi...

May 30, 2023

Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients

Stanford scientist who broke genome sequencing record o...

Mar 22, 2023

Opinion: Listen: Physicians have a moral and professional obligation to get into ‘good trouble’

Opinion: Listen: Physicians have a moral and profession...

Jun 14, 2023